Acute Myeloid Leukemia

Pathophysiology

Acute myeloid leukemia (AML) is a hematologic malignancy characterized by the accumulation of malignant blasts in the bone marrow and peripheral blood.1,2 Disease pathogenesis is driven by the accumulation of genetic modifications, including chromosomal abnormalities and somatic mutations, that alter the epigenetic landscape, gene expression, and cellular function.1-4

Landscape

The prognosis of patients with AML remains poor, and the current standard of care includes intensive chemotherapy regimens.5-7 Research areas for improved AML disease management include high relapse rates, refractory disease, disease-related symptoms and psychological burden, cytogenetic and molecular studies, and increases in the risk of AML-driven second primary malignancy.5,7 Current and emerging research includes evaluation of intensive chemotherapy, small-molecule inhibitors, and immunotherapeutics.6,7

Read more Collapse

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

View Molecular Pathways

In Our Pipeline

Choose filters to find specific trials in the BMS pipeline.

Filter trials by:

STATUS

PHASE

trials
View Acute Myeloid Leukemia Trials Through Our Pipeline

To search for clinical trials with other recruiting statuses,
please visit bolderscience.com.

Clinical trial information is sourced from ClinicalTrials.gov. Information is updated manually as clinical trials are published. The efficacy and safety of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

References

  1. Liesveld JL, Lichtman MA. In: Lichtman MA, et al. Williams Hematology. 7th ed. New York, NY: McGraw-Hill; 2005.
  2. Conway O’Brien E, et al. Adv Hematol. 2014;2014:103175. PMID: 24778653
  3. Licht JD, Sternberg DW. Hematology Am Soc Hematol Educ Program. 2005:137-142. PMID: 16304371
  4. Abdel-Wahab O, Levine RL. Blood. 2013;121:3563-3572. PMID: 23640996
  5. Wiese M, Daver N. Am J Manag Care. 2018;24:S347-S355. PMID: 30132678
  6. Cerrano M, Itzykson R. Curr Oncol Rep. 2019;21:16. PMID: 30715623
  7. Mims AS, Blum W. Curr Opin Hematol. 2019;26:88-95. PMID: 30640734